Adverum BiotechnologiesADVM
About: Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Employees: 121
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,280% more call options, than puts
Call options by funds: $414K | Put options by funds: $30K
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
13% more funds holding
Funds holding: 60 [Q1] → 68 (+8) [Q2]
2.58% more ownership
Funds ownership: 86.12% [Q1] → 88.7% (+2.58%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
52% less capital invested
Capital invested by funds: $253M [Q1] → $121M (-$131M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
RBC Capital Luca Issi 40% 1-year accuracy 21 / 53 met price target | 27%upside $10 | Sector Perform Maintained | 5 Nov 2024 |
Truist Securities Joon Lee 66% 1-year accuracy 31 / 47 met price target | 407%upside $40 | Buy Maintained | 14 Aug 2024 |
HC Wainwright & Co. Matthew Caufield 42% 1-year accuracy 18 / 43 met price target | 280%upside $30 | Buy Reiterated | 13 Aug 2024 |
RBC Capital Luca Issi 40% 1-year accuracy 21 / 53 met price target | 52%upside $12 | Sector Perform Maintained | 13 Aug 2024 |
Financial journalist opinion
Based on 3 articles about ADVM published over the past 30 days